Published:
Extraordinary General Meetings Statement - XTL Notifies NASDAQ of Compliance with Marketplace Rule 4350(d)(2)
VALLEY COTTAGE, N.Y., Oct. 10 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) announces the results of its
Extraordinary General Meetings ("EGMs") held earlier today.
The outcome of the EGMs was as follows: all of the resolutions passed and
Jennifer L. Good and Kenneth J. Zuerblis were appointed as External Directors
of the Company until October 10, 2011. Following the EGMs, XTL's Audit
Committee consists of Mr. Zuerblis, Ms. Good and Dr. William Kennedy.
With the election of the External Directors by the shareholders and their
automatic inclusion in the Audit Committee, XTL has notified NASDAQ that it
currently has a valid Audit Committee under the Israeli Companies Act and
NASDAQ Marketplace Rule 4350(d)(2).
ABOUT XTL BIOPHARMACEUTICALS LTD.
XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of
therapeutics for the treatment of diabetic neuropathic pain and HCV. XTL is
developing Bicifadine, a triple reuptake inhibitor of serotonin,
norepinephrine and dopamine, which is currently in a Phase 2b study for the
treatment of diabetic neuropathic pain. XTL has out-licensed its novel
pre-clinical HCV small molecule inhibitor program. XTL is publicly traded on
the NASDAQ and Tel-Aviv Stock Exchanges (Nasdaq: XTLB; TASE: XTL).
SOURCE XTL Biopharmaceuticals Ltd.
Copyright © 2008, PRNewswire
Copyright © 2008, NewsBlaze,
Daily NewsTags: ,MTC,BIO,HEA,PER,NY-XTL-Biopharm-Mtng
_ _Is your favorite bookmark site missing?
Ask for it.
Search News
Daily News
